<qa>  What is the name of the TPO receptor agonist in MDS?There are currently no licensed drugs in the EU to treat thrombocytopenia in MDS patients classified as IPSS lowint-1. Prior studies with romiplostim a TPO receptor agonist in MDS found that baseline concentration of TPO as well as transfusion history were predictive of subsequent response in a retrospective model. The current prospective study has the aim to explore whether both pretreatment variables endogenous TPO, TPO-level, platelet transfusion history can predict the response to subsequent short-term treatment with romiplostim. 